Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.43 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22284784 | 0.99 | PRKCA (0.47) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL22717361 | 0.92 | DGKA (0.44) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL2053507 | 0.91 | RECQL (0.42) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL27534701 | 0.89 | DGKA (0.50) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL27534703 | 0.88 | PPARG (0.51) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL6270899 | 0.88 | DGKA (0.49) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL5275136 | 0.88 | DGKA (0.49) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL789281 | 0.88 | PPARG (0.51) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL23064684 | 0.86 | PPARG (0.50) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL28245819 | 0.86 | PPARG (0.50) | PRKCAPRKCEPRKCQPRKCDDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024210479-A1 | COMPOSITION CONTAINING LOW-MOLECULAR-WEIGHT COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | 주식회사 에스씨엘테라퓨틱스 | 2024-10-10 | — | — | WO | claimed |
| CN-117771242-A | Albumin nanoparticle for encapsulating iron death related drugs and preparation method and application thereof | 宁夏医科大学 | 2024-03-29 | — | — | CN | claimed |
| CN-117503755-A | Medicine for treating hepatic fibrosis, application thereof and CD36 inhibitor | 南方科技大学 | 2024-02-06 | — | — | CN | claimed |
| CN-117462689-A | Composition for treating liver fibrosis and application thereof | 南方科技大学 | 2024-01-30 | — | — | CN | claimed |
| US-20250221953-A1 | TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES | THE UNIVERSITY OF CHICAGO | 2025-07-10 | — | — | US | disclosed |
| CN-117771242-A | Albumin nanoparticle for encapsulating iron death related drugs and preparation method and application thereof | 宁夏医科大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-117771242-A | Albumin nanoparticle for encapsulating iron death related drugs and preparation method and application thereof | 宁夏医科大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-117503755-A | Medicine for treating hepatic fibrosis, application thereof and CD36 inhibitor | 南方科技大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-117462689-A | Composition for treating liver fibrosis and application thereof | 南方科技大学 | 2024-01-30 | — | — | CN | disclosed |
| WO-2023192947-A2 | TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES | THE UNIVERSITY OF CHICAGO (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023023867-A1 | COMPOUNDS FOR REDUCING CHOLESTEROL AND TREATING LIVER AND KIDNEY DISEASE | MCMASTER UNIVERSITY (CA) | 2023-03-02 | — | — | WO | disclosed |
| US-20220273607-A1 | METHODS OF USING MODIFIED CYTOTOXINS TO TREAT CANCER | NORTHWESTERN UNIVERSITY (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220257722-A1 | COMPOSITIONS AND METHODS OF TREATING AND PREVENTING SYSTEMIC COMPLICATIONS OF ACUTE ILLNESS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-18 | — | — | US | disclosed |
| US-20220168262-A1 | AMPHIPHILIC PLATINUM (IV) PRODRUG AND CANCER TREATMENT PROCESS | KENT STATE UNIVERSITY (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2021007322-A1 | METHODS OF USING MODIFIED CYTOTOXINS TO TREAT CANCER | NORTHWESTERN UNIVERSITY (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2020198604-A1 | COMPOSITIONS AND METHODS OF TREATING AND PREVENTING SYSTEMIC COMPLICATIONS OF ACUTE ILLNESS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020190907-A1 | AMPHIPHILIC PLATINUM (IV) PRODRUG AND CANCER TREATMENT PROCESS | KENT STATE UNIVERSITY (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20150045433-A1 | METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY | UNIV COLORADO REGENTS (US) | 2015-02-12 | — | — | US | disclosed |
| WO-2013048591-A1 | METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY BASED ON FATTY ACID LEVELS IN FASTED VERSUS FED PYTHONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20120142776-A1 | METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168262-A1 | AMPHIPHILIC PLATINUM (IV) PRODRUG AND CANCER TREATMENT PROCESS | SLC11A2, FFAR4, MSR1 | PRKCA 2636/4885PRKCE 3237/4885PRKCQ 3376/4885 |
| US-20250221953-A1 | TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES | GPR65, GPR52, GPR84 | PRKCA 577/4885PRKCE 851/4885PRKCQ 2180/4885 |
| US-20220273607-A1 | METHODS OF USING MODIFIED CYTOTOXINS TO TREAT CANCER | SLC47A2, SLC27A2, SLC27A1 | PRKCA 3469/4885PRKCE 3804/4885PRKCQ 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.